C
Chloe Karpinskyj
Researcher at University College London
Publications - 5
Citations - 415
Chloe Karpinskyj is an academic researcher from University College London. The author has contributed to research in topics: Randomized controlled trial & Hormone replacement therapy (menopause). The author has an hindex of 4, co-authored 5 publications receiving 118 citations. Previous affiliations of Chloe Karpinskyj include University of Manchester.
Papers
More filters
Journal ArticleDOI
Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial.
Usha Menon,Aleksandra Gentry-Maharaj,Matthew Burnell,Naveena Singh,Andy Ryan,Chloe Karpinskyj,Giulia Carlino,Julie Taylor,Susan K. Massingham,Maria Raikou,Jatinderpal Kalsi,Robert Woolas,Ranjit Manchanda,Rupali Arora,Laura Casey,Anne Dawnay,Stephen Dobbs,Simon Leeson,Tim Mould,Mourad W Seif,Aarti Sharma,Karin Williamson,Yiling Liu,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Steven J. Skates,Ian Jacobs,Mahesh K.B. Parmar +28 more
TL;DR: The UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) as discussed by the authors was a randomized controlled trial to determine if population screening can reduce deaths due to the disease.
Journal ArticleDOI
Ovarian cancer prevention and screening
TL;DR: Although all agree that there is not yet evidence to support general population screening, recommendations for high-risk screening vary between countries, a key finding from the screening trials has been the better performance of longitudinal algorithms compared with a single cutoff for CA 125.
Journal ArticleDOI
Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy: a nested United Kingdom Collaborative Trial of Ovarian Cancer Screening cohort study.
Aleksandra Gentry-Maharaj,Chloe Karpinskyj,Clara Helene Glazer,Matthew Burnell,Andrew M. Ryan,Lindsay Fraser,Anne Lanceley,Ian Jacobs,Myra S. Hunter,Usha Menon +9 more
TL;DR: Although more women use over-the-counter medicines, behavioral/lifestyle approaches seem to provide better relief of vasomotor symptoms (VMS) upon discontinuation of HT.
Journal ArticleDOI
Ovarian Cancer Screening and Mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): A Randomized Controlled Trial
Ian Jacobs,Usha Menon,Andrew M. Ryan,Aleksandra Gentry-Maharaj,Matthew Burnell,Jatinderpal Kalsi,Nazar Najib Amso,Sophia Apostolidou,Elizabeth Benjamin,Derek Cruickshank,Danielle N. Crump,Susan K Davies,Anne Dawnay,Stephen Dobbs,Gwendolen Fletcher,Jeremy Ford,Keith M. Godfrey,Richard Gunu,Mariam Habib,Rachel Hallett,Jonathan Herod,Howard Jenkins,Chloe Karpinskyj,Simon Leeson,Sara Lewis,William R. Liston,Alberto Lopes,Tim Mould,John Murdoch,David E. Oram,Dustin J. Rabideau,K. Reynolds,Ian A Scott,Mourad W. Seif,A. Sharma,Naveena Singh,Julie Taylor,Fiona Warburton,Martin Widschwendter,Karin Williamson,Robert Woolas,Lesley Fallowfield,Alistair McGuire,Stuart Campbell,Mahesh K. B. Parmar,Steven J. Skates +45 more
TL;DR: The primary study outcome was death due to OC by December 31, 2014, and the relative mortality reduction over years 0 to 14 was 15% (95% confidence interval, −3 to 30; P = 0.10) with MMS and 11% (−7 to 27) with USS.
Journal ArticleDOI
Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women.
Aleksandra Gentry-Maharaj,Oleg Blyuss,Oleg Blyuss,Andy Ryan,Matthew Burnell,Chloe Karpinskyj,Richard Gunu,Jatinderpal Kalsi,Anne Dawnay,Inés P. Mariño,Ranjit Manchanda,Ranjit Manchanda,Karen H. Lu,Wei Lei Yang,John F. Timms,M. Parmar,Steven J. Skates,Robert C. Bast,Ian Jacobs,Ian Jacobs,Alexey Zaikin,Usha Menon +21 more
TL;DR: It is suggested that longitudinal HE4, CA72-4, anti-TP53 autoantibodies adds little value to longitudinal serum CA125 as a first-line test in ovarian cancer screening of postmenopausal women.